Purple Biotech (PPBT) Competitors $0.61 +0.02 (+2.63%) Closing price 04:00 PM EasternExtended Trading$0.61 +0.00 (+0.26%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. CVKD, ALVR, DARE, KLTO, RNTX, KZR, PASG, MIRA, ENLV, and MBRXShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Cadrenal Therapeutics (CVKD), AlloVir (ALVR), Dare Bioscience (DARE), Klotho Neurosciences (KLTO), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), Passage Bio (PASG), MIRA Pharmaceuticals (MIRA), Enlivex Therapeutics (ENLV), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Its Competitors Cadrenal Therapeutics AlloVir Dare Bioscience Klotho Neurosciences Rein Therapeutics Kezar Life Sciences Passage Bio MIRA Pharmaceuticals Enlivex Therapeutics Moleculin Biotech Purple Biotech (NASDAQ:PPBT) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment. Does the media refer more to PPBT or CVKD? In the previous week, Cadrenal Therapeutics had 6 more articles in the media than Purple Biotech. MarketBeat recorded 7 mentions for Cadrenal Therapeutics and 1 mentions for Purple Biotech. Cadrenal Therapeutics' average media sentiment score of -0.39 beat Purple Biotech's score of -1.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Purple Biotech Negative Cadrenal Therapeutics Neutral Which has stronger earnings and valuation, PPBT or CVKD? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPurple BiotechN/AN/A-$7.24M-$0.42-1.45Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.52 Do analysts prefer PPBT or CVKD? Purple Biotech currently has a consensus target price of $33.00, indicating a potential upside of 5,315.16%. Cadrenal Therapeutics has a consensus target price of $32.00, indicating a potential upside of 136.51%. Given Purple Biotech's higher possible upside, research analysts plainly believe Purple Biotech is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals have more ownership in PPBT or CVKD? 9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, PPBT or CVKD? Purple Biotech has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Is PPBT or CVKD more profitable? Purple Biotech's return on equity of -14.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Purple BiotechN/A -14.00% -12.52% Cadrenal Therapeutics N/A -265.37%-196.38% SummaryPurple Biotech beats Cadrenal Therapeutics on 6 of the 10 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.63M$3.35B$6.15B$10.62BDividend YieldN/A2.28%5.64%4.69%P/E RatioN/A22.1685.6627.13Price / SalesN/A266.37527.36205.87Price / CashN/A46.3226.3031.10Price / Book0.059.9612.926.67Net Income-$7.24M-$52.42M$3.30B$276.23M7 Day Performance3.38%5.95%4.80%3.31%1 Month Performance-7.67%11.59%8.11%10.76%1 Year Performance-87.74%25.01%75.85%33.58% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech1.4376 of 5 stars$0.61+2.6%$33.00+5,315.2%-88.1%$7.63MN/A0.0020Negative NewsShort Interest ↑CVKDCadrenal Therapeutics2.4717 of 5 stars$13.42-4.3%$32.00+138.5%+18.2%$28.72MN/A-1.514ALVRAlloVirN/A$5.61+17.6%N/A-63.2%$28.29MN/A-0.28110High Trading VolumeDAREDare Bioscience1.248 of 5 stars$2.09flat$10.00+378.5%-32.5%$28.17M$10K-0.9830News CoverageKLTOKlotho Neurosciences0.6461 of 5 stars$0.51+11.3%N/AN/A$27.91MN/A-1.12N/ARNTXRein Therapeutics3.1051 of 5 stars$1.15-2.5%$10.00+769.6%N/A$27.50MN/A-0.439KZRKezar Life Sciences2.5584 of 5 stars$3.59-1.6%$9.00+150.7%-50.8%$26.73M$7M-0.3760Positive NewsPASGPassage Bio3.3319 of 5 stars$8.14+1.8%$75.67+829.6%-38.8%$25.43MN/A-0.45130News CoverageGap UpMIRAMIRA Pharmaceuticals0.558 of 5 stars$1.33+0.8%N/A+17.4%$25.17MN/A-2.712Analyst UpgradeENLVEnlivex Therapeutics2.7834 of 5 stars$1.01-1.9%$10.00+890.1%-33.3%$25.02MN/A-1.7470MBRXMoleculin Biotech3.0462 of 5 stars$0.49-1.0%$4.00+721.5%-80.4%$24.35MN/A0.0020Analyst Downgrade Related Companies and Tools Related Companies Cadrenal Therapeutics Competitors AlloVir Competitors Dare Bioscience Competitors Klotho Neurosciences Competitors Rein Therapeutics Competitors Kezar Life Sciences Competitors Passage Bio Competitors MIRA Pharmaceuticals Competitors Enlivex Therapeutics Competitors Moleculin Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
